Eli Lilly (NYSE:LLY) on Friday said that its recently approved eczema therapy Ebglyss led to complete skin clearance in 50% ...
As a federal court in Texas hears a case pitting the FDA versus compounders who want to continue to manufacture cheaper ...
Eli Lilly (NYSE:LLY) saw a notable 10% increase in its stock price over the last month, driven by several important events.
Two recent documents—one from the FDA, the other from a commission organized by The Lancet Diabetes & Endocrinology—indicate ...
A federal court in Texas has rejected a request by producers of compounded drugs to extend their ability to manufacture ...
Late-breaking results from Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) found adolescent patients (ages 12 to under 18) with severe alopecia areata (AA) treated with once-daily ...
Pharmaceutical giant expects the move will create 3,000 high-skilled jobs and provide work for approximately 10,000 ...
The move positions Lilly as a competitive alternative to compounded weight-loss drugs, especially as the FDA cracks down ... Cardiometabolic Health at Eli Lilly and Company, told Health.
Eli Lilly partnered up with telehealth providers LifeMD and Teladoc Health to offer its lower cost, single-vial ...
The partnership comes as telehealth companies grapple with restrictions on the sale of some compounded GLP-1s.
In this week’s edition of InnovationRx, we look at Eli Lilly’s weight-loss pill stockpiling, scaling stem cell manufacturing, ...
Eli Lilly (LLY) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.